Syntis Bio, Inc. is a new company based in Boston that is joining the rush to develop oral drugs for obesity. The company believes it has an original approach – harnessing the small intestine’s biology for digestion and drug absorption – that will separate it from the pack, however.
Key Takeaways
- Syntis Bio is a new company focused on the development of oral drugs for obesity focused on the small intestine.
The company made its public debut on 11 June, announcing its launch as a clinical-stage company. Syntis Bio was originally...








